Table 3.
List of active and ongoing clinical trials investigating cancer vaccines for TNBC.
| Trial (National Clinical Trial ID) | Phase | Condition | Interventions |
|---|---|---|---|
| NCT03362060 | I | TNBC Metastatic TNBC |
Drug: Pembrolizumab Biological: PVX-410 |
| NCT02826434 | I | BC | Biological: PVX-410 Biological: Durvalumab Drug: Hiltonol |
| NCT04105582 | I | TNBC BC |
Biological: Neo-antigen pulsed DCs |
| NCT02316457 | I | TNBC | Biological: IVAC_W_bre1_uID Biological: IVAC_W_bre1_uID/IVAC_M_uID |
| NCT03199040 | I | TNBC Metastatic TNBC |
Drug: Durvalumab Biological: Neoantigen DNA vaccine Device: TDS-IM system (Inchor Medical Systems) |
| NCT04024800 | II | TNBC | Biological: AE37 Peptide vaccine Biological: Pembrolizumab |
Pembrolizumab: FDA-approved anti-PD-1 antagonist monoclonal antibody; PVX-410 and AE37: investigational peptide therapeutic as cancer vaccine. IVAC_W_bre1_uID: Individualized Cancer Immunotherapy patient-specific liposome complexed RNA tailored to the antigen-expression profile of any given patient’s tumour. IVAC_M_uID: Individualized Cancer Immunotherapy treatment with de novo synthesized RNAs targeting up to 20 individual tumour mutations. TDS-IM system: a dermal DNA vaccine delivery system.